OBJECTIVE: The perimenopausal increase in circulating dehydroepiandrosterone sulfate (DHEAS) levels during the menopausal transition (MT) is accompanied by other adrenal steroids that have the potential to alter estrogen/androgen balance and explain the wide interwoman range of estrogen-related symptoms experienced during the MT. METHODS: Annual serum samples from the Study of Women's Health Across the Nation, which had previously been analyzed for immunoreactive estradiol (E2), testosterone, DHEAS, and sex hormone-binding globulin, were selected based on DHEAS concentration and analyzed for immunoreactive and bioactive estrogens and androgens, including immunoreactive androstenedione, dehydroepiandrosterone, and 5-androstene-3β,17β-diol (androstenediol [Adiol]). RESULTS: A two-fold increase in circulating androstenedione and testosterone was found to rise in parallel with the rise in circulating DHEAS, whereas dehydroepiandrosterone and Adiol concentrations rose seven- to eight-fold. Circulating Adiol, which has both androgenic and estrogenic biological activity, was significantly associated (P < 0.02) with circulating estrogen bioactivity only when E2 concentrations were low and Adiol levels were high. CONCLUSIONS: The wide range of circulating levels of Adiol and its contribution to total circulating estrogenicity during the MT is consistent with the observed interwoman difference in symptoms at this time. Therefore, we conclude that Adiol contributes to circulating estrogenicity when E2 production falls at menopause and may contribute significantly to the endocrine changes experienced by midlife women.
OBJECTIVE: The perimenopausal increase in circulating dehydroepiandrosterone sulfate (DHEAS) levels during the menopausal transition (MT) is accompanied by other adrenal steroids that have the potential to alter estrogen/androgen balance and explain the wide interwoman range of estrogen-related symptoms experienced during the MT. METHODS: Annual serum samples from the Study of Women's Health Across the Nation, which had previously been analyzed for immunoreactive estradiol (E2), testosterone, DHEAS, and sex hormone-binding globulin, were selected based on DHEAS concentration and analyzed for immunoreactive and bioactive estrogens and androgens, including immunoreactive androstenedione, dehydroepiandrosterone, and 5-androstene-3β,17β-diol (androstenediol [Adiol]). RESULTS: A two-fold increase in circulating androstenedione and testosterone was found to rise in parallel with the rise in circulating DHEAS, whereas dehydroepiandrosterone and Adiol concentrations rose seven- to eight-fold. Circulating Adiol, which has both androgenic and estrogenic biological activity, was significantly associated (P < 0.02) with circulating estrogen bioactivity only when E2 concentrations were low and Adiol levels were high. CONCLUSIONS: The wide range of circulating levels of Adiol and its contribution to total circulating estrogenicity during the MT is consistent with the observed interwoman difference in symptoms at this time. Therefore, we conclude that Adiol contributes to circulating estrogenicity when E2 production falls at menopause and may contribute significantly to the endocrine changes experienced by midlife women.
Authors: J F Dorgan; F Z Stanczyk; C Longcope; H E Stephenson; L Chang; R Miller; C Franz; R T Falk; L Kahle Journal: Cancer Epidemiol Biomarkers Prev Date: 1997-03 Impact factor: 4.254
Authors: Bill L Lasley; Nanette Santoro; John F Randolf; Ellen B Gold; Sybil Crawford; Gerson Weiss; Daniel S McConnell; Mary Fran Sowers Journal: J Clin Endocrinol Metab Date: 2002-08 Impact factor: 5.958
Authors: John F Randolph; MaryFran Sowers; Ellen B Gold; Beth A Mohr; Judith Luborsky; Nanette Santoro; Daniel S McConnell; Joel S Finkelstein; Stanley G Korenman; Karen A Matthews; Barbara Sternfeld; Bill L Lasley Journal: J Clin Endocrinol Metab Date: 2003-04 Impact factor: 5.958
Authors: U Goebelsmann; R Horton; J H Mestman; J J Arce; Y Nagata; R M Nakamura; I H Thorneycroft; D R Mishell Journal: J Clin Endocrinol Metab Date: 1973-05 Impact factor: 5.958
Authors: Bill L Lasley; Sybil L Crawford; Gail A Laughlin; Nanette Santoro; Daniel S McConnell; Carolyn Crandall; Gail A Greendale; Alex J Polotsky; Marike Vuga Journal: Menopause Date: 2011-05 Impact factor: 2.953
Authors: Jiangang Chen; Twanda L Thirkill; Peter N Lohstroh; Susan R Bielmeier; Michael G Narotsky; Deborah S Best; Randy A Harrison; Kala Natarajan; Rex A Pegram; James W Overstreet; Bill L Lasley; Gordon C Douglas Journal: Toxicol Sci Date: 2003-12-22 Impact factor: 4.849
Authors: Alan J Conley; Frank Z Stanczyk; John H Morrison; Pawel Borowicz; Kurt Benirschke; Nancy A Gee; Bill L Lasley Journal: Menopause Date: 2013-03 Impact factor: 2.953
Authors: Ping G Tepper; Maria M Brooks; John F Randolph; Sybil L Crawford; Samar R El Khoudary; Ellen B Gold; Bill L Lasley; Bobby Jones; Hadine Joffe; Rachel Hess; Nancy E Avis; Sioban Harlow; Daniel S McConnell; Joyce T Bromberger; Huiyong Zheng; Kristine Ruppert; Rebecca C Thurston Journal: Menopause Date: 2016-10 Impact factor: 2.953
Authors: MacKenzie R Peltier; José M Flores; Philip H Smith; Walter Roberts; Terril L Verplaetse; Kelly E Moore; Robyn Hacker; Lindsay M Oberleitner; Sherry A McKee Journal: Nicotine Tob Res Date: 2020-05-26 Impact factor: 4.244
Authors: Juilee Rege; Shigehiro Karashima; Antonio M Lerario; Joshua M Smith; Richard J Auchus; Josephine Z Kasa-Vubu; Hironobu Sasano; Yasuhiro Nakamura; Perrin C White; William E Rainey Journal: J Clin Endocrinol Metab Date: 2016-09-13 Impact factor: 5.958
Authors: Muhammad Zahid; Whitney Goldner; Cheryl L Beseler; Eleanor G Rogan; Ercole L Cavalieri Journal: Int J Cancer Date: 2013-06-14 Impact factor: 7.396